Shopping Cart
- Remove All
- Your shopping cart is currently empty
Keap1-Nrf2-IN-28 (SG16) is an orally active inhibitor of Keap1-Nrf2. It demonstrates antioxidant properties and upregulates the expression of Nrf2, HO-1, GCLM, and Akr1c1. Additionally, Keap1-Nrf2-IN-28 can mitigate acute liver injury induced by APAP.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | Keap1-Nrf2-IN-28 (SG16) is an orally active inhibitor of Keap1-Nrf2. It demonstrates antioxidant properties and upregulates the expression of Nrf2, HO-1, GCLM, and Akr1c1. Additionally, Keap1-Nrf2-IN-28 can mitigate acute liver injury induced by APAP. |
In vitro | Keap1-Nrf2-IN-28 (Compound SG16) at a concentration of 10 μM for 16 hours significantly induces a 10.7-fold increase in HO-1 expression in AML12 cells, demonstrating its Nrf2 induction capability. Additionally, Keap1-Nrf2-IN-28 (0-10 μM, 16 hours) enhances the mRNA expression of HO-1, GCLM, and Akr1c1, as well as the protein expression of Nrf2, HO-1, and GCLM in AML12 cells. |
In vivo | Keap1-Nrf2-IN-28 (Compound SG16), administered intraperitoneally at doses of 12.5 or 25 mg/kg, can protect mice from acute liver injury (ALI) induced by APAP. At 25 mg/kg, intraperitoneally, it shows no liver protective effects in Nrf2 knockout mice. When given at 25 mg/kg to C57BL/6J mice, Keap1-Nrf2-IN-28 demonstrates good biocompatibility with no observed organ toxicity. |
Molecular Weight | 425.43 |
Formula | C22H16FNO5S |
Cas No. | 3075750-60-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.